Sandbox:Roukoz: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
{{familytree | | | | | | | | | C01 | | | | | |C01=Histopathologic examination}} | {{familytree | | | | | | | | | C01 | | | | | |C01=Histopathologic examination}} | ||
{{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }} | {{familytree | | |,|-|-|-|-|-|-|+|-|-|-|-|-|-|.| }} | ||
{{familytree | | D01 | | | | | D02 | | | | | D03 |D01=Squamous cell carcinoma|D02=Adenocarcinoma and poorly differntiated carcinoma|D03=Neuroendocrine carcinoma}} | {{familytree | | D01 | | | | | D02 | | | | | D03 |D01='''Squamous cell carcinoma'''|D02='''Adenocarcinoma and poorly differntiated carcinoma'''|D03='''Neuroendocrine carcinoma'''}} | ||
{{familytree | | |!| | | | | | |!| | | | | | |!| }} | {{familytree | | |!| | | | | | |!| | | | | | |!| }} | ||
{{familytree | |E01| | | | | E02| | | | |boxstyle=text-align: left; |E03| |E01=Additional tests specific to location of metastasis|E02=Gender specific tests|E03=• Octreoscan<br> • Plasma chromogranin A}} | {{familytree | |E01| | | | | E02| | | | |boxstyle=text-align: left; |E03| |E01=Additional tests specific to location of metastasis|E02=Gender specific tests|E03=• Octreoscan<br> • Plasma chromogranin A}} | ||
{{familytree | | | | | | | |,|-|^|-|.| | | | | | }} | {{familytree |,|^|.| | | | |,|-|^|-|.| | | | | | }} | ||
{{familytree | | | | | |boxstyle=text-align: left; | | {{familytree |F01|F02|F03| | |boxstyle=text-align: left; |F04| | | |F05| | | | |F04='''Male'''<br> • PSA <br> • aFP <br> • BHCG|F05='''Female'''<br> • Mammography <br> • Ultrasound or pelvic CT}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 18:37, 10 October 2018
| Tumor of unknown primary origin | |||||||||||||||||||||||||||||||||||||||||||||||
| • Full medical history and physical exam • Basic blood and bichemical analysis • CT scan of chest, abdomen, and pelvis | |||||||||||||||||||||||||||||||||||||||||||||||
| Histopathologic examination | |||||||||||||||||||||||||||||||||||||||||||||||
| Squamous cell carcinoma | Adenocarcinoma and poorly differntiated carcinoma | Neuroendocrine carcinoma | |||||||||||||||||||||||||||||||||||||||||||||
| Additional tests specific to location of metastasis | Gender specific tests | • Octreoscan • Plasma chromogranin A | |||||||||||||||||||||||||||||||||||||||||||||
| {{{F01}}} | {{{F02}}} | {{{F03}}} | Male • PSA • aFP • BHCG | Female • Mammography • Ultrasound or pelvic CT | |||||||||||||||||||||||||||||||||||||||||||